drugset / Trial / NCT02996214

Paclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study(LIPUSU)

NCT02996214

Phase 4 Unknown 536 enrolled Nanjing Luye Sike Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the efficacy and the safety of paclitaxel liposome and cisplatin compared with gemcitabine and cisplatin as first-line therapy in advanced squamous non-small-cell lung cancer .

Timeline

Start
2016-11
Primary completion
2019-12
Completion
2020-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gemcitabine Small molecule 1000 mg/m2
Subject Paclitaxel Small molecule 175 mg/m2
Background Cisplatin Other / unclassified 75 mg/m2